FDA-approved poly(ethylene glycol)–protein conjugate drugs

PEGylation or covalent attachment of poly(ethylene glycol) improves the pharmacokinetic properties of protein drugs. In vivo circulation lifetimes are increased and dosages are decreased, resulting in improved patient quality of life. PEG may be attached to proteins using a variety of different chemical reactions. This review discusses currently available FDA-approved PEGylated protein drugs, their intended use and target, and the PEG attachment chemistry utilized.

[1]  F. C. Dougherty,et al.  Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[2]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[3]  H. Maynard,et al.  Protein-polymer conjugates: synthetic approaches by controlled radical polymerizations and interesting applications. , 2010, Current opinion in chemical biology.

[4]  A. Chilkoti,et al.  In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation , 2010, Proceedings of the National Academy of Sciences.

[5]  Graeme Moad,et al.  Radical addition-fragmentation chemistry in polymer synthesis , 2008 .

[6]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[7]  F. Perez-Ruiz,et al.  PEG-uricase in the management of treatment-resistant gout and hyperuricemia. , 2008, Advanced drug delivery reviews.

[8]  J. M. Harris,et al.  Pegylation: a novel process for modifying pharmacokinetics. , 2001, Clinical pharmacokinetics.

[9]  S. Pedder,et al.  Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. , 2002, Advanced drug delivery reviews.

[10]  K. Matyjaszewski,et al.  Atom transfer radical polymerization. , 2001, Chemical reviews.

[11]  Harm-Anton Klok,et al.  Peptide/protein-polymer conjugates: synthetic strategies and design concepts. , 2008, Chemical communications.

[12]  K. Matyjaszewski,et al.  Functional polymers by atom transfer radical polymerization , 2001 .

[13]  P. Keegan,et al.  FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). , 2007, The oncologist.

[14]  D. Scarlata,et al.  Darbepoetin alfa Administered Every Other Week Maintains Hemoglobin Levels over 52 Weeks in Patients with Chronic Kidney Disease Converting from Once-Weekly Recombinant Human Erythropoietin: Results from Simplify the Treatment of Anemia with Aranesp (STAAR) , 2006, American Journal of Nephrology.

[15]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[16]  F. Davis,et al.  Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.

[17]  U. Schubert,et al.  Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.

[18]  P. Schultz,et al.  Beyond the Canonical 20 Amino Acids: Expanding the Genetic Lexicon* , 2010, The Journal of Biological Chemistry.

[19]  J. Adamson,et al.  Design and Chemical Synthesis of a Homogeneous Polymer-Modified Erythropoiesis Protein , 2003, Science.

[20]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[21]  R. Duncan.  The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[22]  P. Voûte,et al.  An open‐label, multicenter study of polyethylene glycol‐L‐asparaginase for the treatment of acute lymphoblastic leukemia , 1995, Cancer.

[23]  C. Barner‐Kowollik,et al.  In situ formation of protein-polymer conjugates through reversible addition fragmentation chain transfer polymerization. , 2007, Angewandte Chemie.

[24]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[25]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[26]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[27]  M. Piccart,et al.  A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  J. Gabrilove,et al.  Filgrastim (r-metHuG-CSF): the first 10 years. , 1996, Blood.

[29]  J. Nicolas,et al.  Recent advances in the design of bioconjugates from controlled/living radical polymerization , 2010 .

[30]  S Davis,et al.  Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. , 1981, Clinical and experimental immunology.

[31]  G. Molineux.  The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). , 2004, Current pharmaceutical design.

[32]  F. Veronese,et al.  The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.

[33]  David A. Tirrell,et al.  Non‐Canonical Amino Acids in Protein Polymer Design , 2007 .

[34]  L. R. Hill,et al.  Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Bentley,et al.  Chemistry for peptide and protein PEGylation. , 2002, Advanced drug delivery reviews.

[36]  R. Ross,et al.  Pegvisomant: structure and function. , 2002, Journal of molecular endocrinology.

[37]  H. Maynard,et al.  Streptavidin as a macroinitiator for polymerization: in situ protein-polymer conjugate formation. , 2005, Journal of the American Chemical Society.

[38]  J. Stadler,et al.  PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies , 2007, Drug Metabolism and Disposition.

[39]  M. Keating,et al.  Clinical pharmacology of polyethylene glycol-L-asparaginase. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[40]  L. Moreland,et al.  Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. , 2008, Arthritis and rheumatism.

[41]  Lei Xie,et al.  Structural and Biologic Characterization of Pegylated Recombinant IFN-α2b , 2001 .

[42]  A. Nesbitt,et al.  Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor &agr; agents , 2007, Inflammatory bowel diseases.

[43]  S. Schreiber,et al.  Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.

[44]  M. Hershfield,et al.  Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. , 2007, Arthritis and rheumatism.

[45]  R. Broyer,et al.  Emerging synthetic approaches for protein-polymer conjugations. , 2011, Chemical communications.

[46]  Ruth Duncan,et al.  Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.

[47]  G. Moad,et al.  Toward living radical polymerization. , 2008, Accounts of chemical research.

[48]  J. H. Kim,et al.  Inhibition of leukemias in man by L-asparaginase. , 1967, Cancer research.

[49]  F. Veronese,et al.  Improvement of Drug Therapy by Covalent PEG Conjugation: An Overview From a Research Laboratory , 2010 .

[50]  D. Goeddel,et al.  Rational design of potent antagonists to the human growth hormone receptor. , 1992, Science.

[51]  G. Pasut,et al.  Polymer-drug conjugation, recent achievements and general strategies , 2007 .

[52]  T. Wagner,et al.  Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[53]  B. Bax,et al.  In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol‐conjugated and native adenosine deaminase , 2000, British journal of haematology.

[54]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.

[55]  R. Bukowski,et al.  Treating cancer with PEG Intron , 2002, Cancer.

[56]  A. Alikhani,et al.  Native protein-initiated ATRP: a viable and potentially superior alternative to PEGylation for stabilizing biologics. , 2009, Acta biomaterialia.

[57]  C Simone Fishburn,et al.  The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. , 2008, Journal of pharmaceutical sciences.

[58]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[59]  F. C. Dougherty,et al.  Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration* , 2007, Current medical research and opinion.

[60]  Krzysztof Matyjaszewski,et al.  Controlled/“Living” Radical Polymerization. Kinetics of the Homogeneous Atom Transfer Radical Polymerization of Styrene , 1997 .

[61]  Graeme Moad,et al.  Living radical polymerization by the RAFT process , 2005 .

[62]  H. Maynard,et al.  Synthesis of protein-polymer conjugates. , 2007, Organic & biomolecular chemistry.

[63]  Todd Emrick,et al.  PEG- and peptide-grafted aliphatic polyesters by click chemistry. , 2005, Journal of the American Chemical Society.

[64]  I. Macdougall,et al.  Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia , 2006, The Lancet.

[65]  P. Caliceti,et al.  In situ growth of side-chain PEG polymers from functionalized human growth hormone-a new technique for preparation of enhanced protein-polymer conjugates. , 2010, Bioconjugate chemistry.

[66]  R. Kobayashi,et al.  Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.

[67]  B. Wiens,et al.  First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M. Francis,et al.  Optimization of a biomimetic transamination reaction. , 2008, Journal of the American Chemical Society.

[69]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[70]  J. Broome.  Evidence that the L-Asparaginase Activity of Guinea Pig Serum is responsible for its Antilymphoma Effects , 1961, Nature.

[71]  J. A. Scarlett,et al.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist , 2001, The Lancet.